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Abstract
Objective—Cytochrome P450 epoxygenases (CYP) metabolize arachidonic acid to 
epoxyeicosatrienoic acids (EETs), which exhibit vasodilatory, anti-inflammatory and 
neuroprotective actions in experimental cerebral ischemia. We evaluated the effect of endothelial-
specific CYP overexpression on cerebral blood flow, inflammatory cytokine expression and tissue 
infarction after focal cerebral ischemia in transgenic mice.
Approach and Results—Male and female wild-type and transgenic mice overexpressing either 
human CYP2J2 or CYP2C8 epoxygenases in vascular endothelium under control of the Tie2 
promoter (Tie2-CYP2J2 and Tie2-CYP2C8) were subjected to 60-minutes middle cerebral artery 
occlusion (MCAO). Microvascular cortical perfusion was monitored during vascular occlusion and 
reperfusion using laser-Doppler flowmetry and optical imaging. Infarct size and inflammatory 
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cytokines were measured at 24 hours of reperfusion by TTC and real-time quantitative PCR, 
respectively. Infarct size was significantly reduced in both Tie2-CYP2J2 and Tie2-CYP2C8 
transgenic male mice compared to corresponding WT male mice (n=10 per group, p < 0.05). Tie2-
CYP2J2, but not Tie2-CYP2C8 male mice maintained higher blood flow during MCAO; however, 
both Tie2-CYP2J2 and Tie2-CYP2C8 had lower inflammatory cytokine expression after ischemia 
compared to corresponding WT males (n=10 per group for CBF and n=3 for cytokines, p<0.05). 
In females, a reduction in infarct was observed in the caudate-putamen, but not in the cortex or 
hemisphere as a whole and no differences were observed in blood flow between female transgenic 
and WT mice (n=10 per group).
Conclusions—Overexpression of CYP epoxygenases in vascular endothelial cells protects 
against experimental cerebral ischemia in male mice. The mechanism of protection is in part 
linked to enhanced blood flow and suppression of inflammation, and is both sex- and CYP 
isoform-specific.
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Introduction
Arachidonic acid (AA) is a polyunsaturated fatty acid present in cell membranes as part of 
their phospholipid pool (Liu et al., 2004). Free AA is released into cytosol upon stimulation 
by endogenous agonists, pharmacological agents and following injury, such as ischemic 
injury, where it is metabolized into biologically active eicosanoids by one of three enzymatic 
pathways: the cyclooxygenase (COX), lipoxygenase (LOX) or cytochrome P450 
monooxygenase (CYP) pathway. There are two broad classes of CYP enzymes involved in 
eicosanoid formation: 1) the hydroxylases, which form 20-hydroxyeicosatetraenoic acid, a 
vasoconstrictor in the cerebral and coronary circulation; and 2) the epoxygenases, which 
form epoxyeicosatrienoic acids (EETs), which are vasodilators and protective against 
ischemic brain and heart injury by multiple mechanisms. In addition to vasodilation, EETs 
possess anti-inflammatory, anti-apoptotic and anti-oxidant properties (Spector and Norris, 
2007). In the brain, EETs are produced by astrocytes (Alkayed et al., 1996), vascular 
endothelium (Medhora et al., 2001) and perivascular nerves (Iliff et al., 2007), where they 
have been implicated in functional hyperemia following neuronal activation (Alkayed et al., 
1997, Harder et al., 1998). Interestingly, CYP epoxygenase upregulation in brain after 
ischemic preconditioning has been associated with tissue protection with no change in blood 
flow (Alkayed et al., 2002), suggesting that EETs may exert a neuroprotective effect that is 
independent from its established vasodilator effect. In contrast, stabilizing endogenous EETs 
by deleting their metabolizing enzyme soluble epoxide hydrolase (sEH) is protective against 
ischemic injury, and protection is clearly associated with increased vasodilation in response 
to focal cerebral ischemia (Zhang et al., 2008). Whether different regioisomers of EETs have 
different mechanisms of action and may account for these apparent differences following 
ischemia (neuroprotection versus vasodilation) is not well understood. Also, the contribution 
of EETs derived from different cell types to protection following ischemia has not been fully 
elucidated.
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To determine the contribution of endothelial-derived EETs to protection following ischemia, 
we compared brain infarct and cerebral blood flow (CBF) during middle cerebral artery 
occlusion (MCAO) in transgenic mice overexpressing one of two human CYP epoxygenase 
isoforms, hCYP2J2 or hCYP2C8, in vascular endothelium. Our findings suggest that 
overexpression of CYP epoxygenase in vascular endothelium protects against experimental 
cerebral ischemia. The mechanism of protection is in part linked to enhanced blood flow and 
suppression of inflammation, and is both sex- and CYP isoform-specific.
Materials and Methods
The study was conducted in accordance with the National Institutes of Health guidelines for 
the care and use of animals in research, and protocols were approved by the Animal Care 
and Use Committee of Oregon Health and Science University (Portland, OR, USA).
Animals
Transgenic mice expressing either the human CYP2J2 or CYP2C8 epoxygenase in vascular 
endothelium under the control of the murine Tie2 promoter (2-kb) and full enhancer (10-kb) 
were generated on a C57Bl/6 background. We used heterozygous Tie2-CYP2J2, Tie2-
CYP2C8 transgenic mice and age- and sex-matched WT littermate controls. Genotype was 
determined in each mouse by PCR of tail genomic DNA. Generation of Tie2-CYP2J2 and 
Tie2-CYP2C8 mice, founder lines, breeding and genotyping protocols have been previously 
described (Lee et al., 2010).
Middle Cerebral Artery Occlusion (MCAO)
Adult (25-28g) male and female wild-type (WT), Tie2-CYP2J2 and Tie2-CYP2C8 
transgenic mice were subjected to 60-min middle cerebral artery occlusion (MCAO) under 
isoflurane anesthesia, as described previously, with slight modifications (Zhang et al., 2008). 
Briefly, mice were anesthetized with isoflurane (induction 5%; maintenance 1.0%), and kept 
warm with water pads. A small laser-Doppler probe was affixed to the skull to monitor 
cerebral cortical perfusion and verify vascular occlusion and reperfusion. A silicone-coated 
6-0 nylon monofilament was inserted into the right internal carotid artery via the external 
carotid artery until laser-Doppler signal dropped to less than 20% of baseline. The animal 
was maintained anesthetized with 1% isoflurane on the surgical station for 60 minutes of 
occlusion. After reperfusion, mice were allowed to recover and observed for 24 hours. 
Infarct size was measured at 24 h after MCAO in 2-mm thick coronal brain sections (five 
total) using 2, 3, 5-triphenyltetrazolium chloride (TTC) staining and digital image analysis. 
Sections were incubated in 1.2% TTC in saline for 15 min at 37°C, and then fixed in 
formalin for 24 h. Slices were photographed; infarcted (unstained) and uninfarcted (red 
color) areas were measured with MCID software (InterFocus Imaging Ltd, Linton, UK) and 
integrated across all five slices. To account for the effect of edema, the infarcted area was 
estimated indirectly by subtracting the uninfarcted area in the ipsilateral hemisphere from 
the contralateral hemisphere, and expressing infarct volume as a percentage of the 
contralateral hemisphere. Cerebrocortical laser-Doppler perfusion (LDP) was monitored 
during occlusion and early reperfusion. The laser-Doppler probe was positioned on bone 
over the dorsolateral parietal cortex 2 mm posterior, 3 mm lateral to the Bregma. The LDP 
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signal was recorded continuously and averaged over 15-minute intervals for comparison 
among treatment groups.
Optical Microangiography (OMAG)
OMAG was performed as previously described (Zhang et al., 2009, An et al., 2010, Wang et 
al., 2007). The mouse head was shaved before OMAG imaging. During imaging, the mouse 
was immobilized on a custom-made stereotaxic stage and lightly anesthetized with 
isoflurane (0.2 l/min O2, 0.8 l/min air). Body temperature was kept at 35.5–36.5°C with a 
warming blanket and monitored by a rectal thermal probe throughout the experiment. An 
incision of ~1 cm was made along the sagittal suture, and the frontal parietal and 
interparietal bones were exposed by pulling the skin to the sides. The animal was then 
positioned under the OMAG scanning probe, allowing for visualization and quantification of 
blood flow based on endogenous light scattering from moving blood cells within biologic 
tissue, with no need to use exogenous contrasting agents. In the mouse, OMAG covers the 
entire thickness of the cerebral cortex through an intact skull. OMAG was an optical 
coherence tomography based imaging technique capable of generating three-dimensional 
images of functional vasculature in vivo and without the need for dye injection (An et al., 
2010, Wang et al., 2007). The OMAG imaging system used in this study employed a 
superluminescent diode with a central wavelength of 1,310 nm and a full-width, half-
maximum bandwidth of 50 nm, providing an axial resolution of ~10 um in tissue. The lateral 
resolution of the system was measured at ~15 um. The spectral interferograms formed by the 
reference light and the light backscattered from the tissue sample were detected by a 
custom-built, high-resolution and high-speed spectrometer, upon which the OMAG 
algorithm was applied to obtain angiographic images representing functional cerebral 
microvasculature within the scanned brain tissue. The three-dimensional scan represented a 
physical volume with the following x–y–z dimensions: 2.5 × 2.5 × 2.0 mm3.
Isolation of Cerebral Vessels
Mice were deeply anesthetized with isoflurane and perfused transcardially with pre-chilled 
heparinized saline (1 U/ml) before decapitation to remove blood from the cerebral 
circulation; brains were then rapidly dissected. Pial and large cerebral vessels were removed 
with fine forceps and discarded. The remaining brain tissue was homogenized in ice-cold 
PBS with a loosely fitting Dounce homogenizer, and centrifuged at 2,000 g for 5 minutes at 
4°C. The supernatant, containing parenchymal brain tissue, was discarded; the pellet, 
containing vessels, was resuspended in PBS and centrifuged at 2,000 g for another 5 minutes 
at 4°C. The second pellet was resuspended in PBS, layered over a 15% dextran density 
gradient (molecular weight 35,000 - 40,000 kDa), and centrifuged in a swinging-bucket 
rotor for 30 minutes at 3,500 g at 4°C. The supernatant was discarded, and the pellet was 
resuspended in PBS, and again layered over dextran and centrifuged for an additional 30 
minutes at 3,500 g. The resulting pellet was washed with ice-cold PBS over a 70 mm nylon 
mesh, cerebral microvessels vessels and capillaries were collected and stored at −80 °C.
Primary aortic endothelial cell isolation
Aorta from WT Tie2-CYP2J2 and Tie2-CYP2C8 male mice were harvested for isolation of 
endothelial cells, as described previously (Lee et al., 2010). Briefly, 3 aortas from each 
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genotype were pooled, minced and digested with type-I collagenase (2 mg/ml, Worthington 
Biochemical Corporation, Lakewood, NJ, USA) at 37°C for 45 min. Resultant homogenates 
were triturated with a 30-ml syringe, filtered through a 70-μm cell strainer, washed with PBS 
+ 0.1% FBS and centrifuged for 10 minutes at 1000rpm. Cell pellets were re-suspended and 
incubated with magnetic Dynabeads (Invitrogen) coated with anti-CD31 antibody (BD 
Biosciences, San Jose, CA, USA). Endothelial cells were isolated by magnetic separation 
and plated onto 0.1% gelatin-coated flasks in DMEM supplemented with 20% FBS, 100 
μg/mL heparin, 100 μg/mL penicillin/streptomycin and 100 μg/mL endothelial cell growth 
supplement (Biomedical Technologies, Stoughton, MA, USA). Once confluent, cells were 
trypsinized and further purified by incubation with anti-CD102 (BD Biosciences) coated 
Dynabeads and grown to confluence. 1 million endothelial cells were plated on 100 mm 
tissue culture dishes and allowed to adhere overnight. Cells were washed with PBS and 
incubated in serum free DMEM for 4 hours. The cell- conditioned medium was collected, 
the cells were then incubated for 10 minutes in fresh serum free DMEM containing 10 μM 
Ca2+ ionophore (A23187, Sigma-Aldrich) to stimulate arachidonic acid release. Both basal 
and stimulated medium were collected and stored at −80°C for MC/MS/MS analysis.
Quantification of CYP-derived eicosanoids in medium
Epoxy and dihydroxy metabolites (EETs and DHETs) of arachidonic acid were extracted 
and quantified; 11,12- and 14,15- regioiosomers specifically were quantified as these are the 
primary metabolic products synthesized by CYP2J2 and CYP2C8 (Zeldin et al., 1995; Wu et 
al., 1996). These were extracted in cell culture medium by solid-phase extraction and eluted 
in ethyl acetate, as described by Newman et al. (2002) and Seubert et al. (2006). Oxylipids 
were separated by reverse-phase HPLC on a 2- × 150-mm, 5-μm Luna C18 (2) column 
(Phenomenex, Torrance, CA, USA) and quantified using a MDS Sciex API 3000 triple 
quadrupole mass spectrometer (Applied Biosystems) with negative mode electrospray 
ionization and multiple reaction monitoring, as previously described (Newman et al., 2002). 
Relative response ratios of each analyte were used to calculate concentrations, quantification 
relative to internal standards corrected for surrogate losses. Cell medium concentrations 
were normalized to cell plating density.
Cerebrospinal fluid (CSF) collection and extraction
Plasma oxylipid levels were determined by liquid chromatography, tandem mass 
spectroscopy (LC/MS/MS). Samples were collected from the cisterna magna of naïve 
animals. Mice were anesthetized and placed prone on a stereotaxic frame. A sagittal incision 
of the skin was made inferior to the occiput, the subcutaneous tissue and muscles separated 
and the dura matter was penetrated with the 30G1 needle connected with PE-10 tube. The 
CSF was drawn into PE-10 tubing with the careful suction by a 10 μl gastight syringe 
(Hamilton Company, Reno, NV, USA). The CSF was injected into an Eppendorf tube, and 
frozen in a −80°C freezer until assayed. CSF samples (5-10 ul) were mixed with 50 ul of 
0.1% acetic acid in 5% methanol, 10 ul of 0.4mg/ml butylated hydroxytolulene, and spiked 
with with 30 ng PGE2-d4, 10,11- DiHN, and 10,11-EpHep (Cayman Chemical, Ann Arbor, 
MI) as internal standards. Oxylipids were extracted 3 times with 1 ml ethyl acetate. Ethyl 
acetate from each sample was pooled and dried under gentle nitrogen flow. Samples were 
reconstituted in 100 ul of 40% ethanol. Three injections of 20 ul were analyzed for each 
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sample. The triplicate sample injections were averaged, corrected for volume of CSF, and 
represented as pg/ul. Online liquid chromatography of extracted samples was performed 
with an Agilent 1200 Series capillary HPLC (Agilent Technologies, Santa Clara, CA, USA) 
as previously described (Edin et al., 2011, Newman et al., 2002). Separations were achieved 
using a Phenomenex Luna C18(2) column (5 um, 150×1 mm; Phenomenex, Torrance, CA, 
USA), which was held at 40°C. Mobile phase A was 85:15:0.1 water:acetonitrile:acetic acid. 
Mobile phase B was 70:30:0.1 acetonitrile:methanol:acetic acid. Gradient elution was used; 
mobile phase percentage B and flow rate were varied as follows: 0% B at 87.5 ul/min at 0 
min, ramp from 0 to 2 min to 25% B at 87.5 ul/min, ramp from 2 to 5 min to 50% B at 60 ul/
min, ramp from 5 to 23 min to 92.5% B at 60 ul/min, ramp from 23 to 23.5 min to 100% B 
at 87.5 ul/min, hold from 23.5 to 29 min at 100% B, ramp from 29 to 29.6 min down to 0% 
B, and hold 0% B to 33 min. Negative ion electrospray ionization tandem mass spectrometry 
was used for detection. Analyses were performed on an MDS Sciex API 3000 equipped with 
a TurboIonSpray source (Applied Biosystems). Turbo desolvation gas was heated to 275°C 
at a flow rate of 5.75 ml/min.
TaqMan Real-Time Quantitative PCR
RNA was isolated from cerebral microvessels using RNAqueous-Micro kit and reverse 
transcribed using the High Capacity cDNA Reverse Transcription Kit; resultant cDNA was 
amplified using TaqMan Universal PCR Master Mix (all Life Technologies, Carlsbad, CA) 
in the ABI Prism 7000 sequence detection system. Quantitative PCR was performed in 96 
well plate format using 50 μl total volume, with each sample run in triplicate. PCR was also 
run on controls in which template had not been added, in order to determine DNA 
contamination and primerdimer formation. RNA with no reverse transcription was also 
included to discount genomic DNA amplification. TNFα (Mm00443258_m1) and IL1-β 
(Mm00434228_m1) gene expression assays (Life Technologies) were used and 18S was 
measured as an internal control using the 18S rRNA control kit FAM-TAMRA (Eurogentec 
SA, Osaka, Japan). Relative quantification analysis was performed using the 2(−Delta Delta 
C(T)) method (Livak et al., 2001).
In situ hybridization
Cloning of human CYP 2C8 and 2J2—Fragments of the human CYP 2C8 and 2J2 
gene were cloned by using TOPO TA Cloning kit (Thermo Fisher Scientific, Waltham, MA). 
The forward primer (bases 869-888; 5’-CAA TCC TCG GGA CTT TAT CG-3’) and reverse 
primer (bases 1182-1163; 5’-GGA CAA GGT CAC TGT ATC TC-3’) for 2C8 were 
designed from the human 2C8 sequence (accession number NM_000770). The forward 
primer (bases 942-961; 5’ ACC GAG ACA ACT TGG ACA AC-3’) and reverse primer 
(bases 1347-1328; 5’-ATG CCC GCT TTC CTA TTG AG-3’) for 2J2 were designed from 
the human 2J2 sequence (accession number NM_000775). The CYP 2C8 and 2J2 fragments 
were amplified from aMHC-2C8 and aMHC-2J2 constructs. PCR was conducted for 40 
cycles of denaturation (95°C, 45 seconds), annealing (61.6°C, 45 seconds), and extension 
(72°C, 1 minute). The resulting 314bp (2C8) and 406bp (2J2) products were subcloned into 
the pCR2.1-TOPO vector (Invitrogen) using the TOPO TA cloning kit according to the 
manufacturer's instruction. The pCR2.1-TOPO vector contains only one promoter (T7), 
therefore, sense and antisense probes required two separate vectors with the respective 
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inserts in the correct orientation for sense and antisense synthesis. The vectors containing 
the inserts were then sequenced to confirm the direction for sense and antisense probe 
synthesis.
Probe preparation—Radioactive antisense and sense cRNA probes were transcribed in 
vitro with T7 RNA polymerase from the BamH1 linearized human CYP 2C8 and 2J2 
constructs in the presence of 35S-uridine 5’ (α-thio)triphosphate (35S-UTP). Residual DNA 
was digested with 2 U DNase I (Ambion Inc. Austin, Texas). The sense and antisense RNA 
probes were purified on a G-50 Sephadex column (Amersham Biosciences, Piscataway, NJ).
Tissue preparation—Wild-type and transgenic animals were anesthetized, killed by 
decapitation and the brains sliced into 2 mm coronal blocks through the rostral forebrain. 
The brain blocks were fixed by immersion in 4% paraformaldehyde in Sorensen buffer (0.03 
M; pH 7.4) for 6 hours at 4°C, rinsed overnight in 20% buffered-sucrose solution (pH 7.4), 
embedded in O.C.T. (Sakura Finetek, Torrance, CA), and frozen in isopentane at −55°C. 
Coronal sections (20 μm) were cut on a cryostat and thaw mounted onto Superfrost Plus 
glass slides (Thermo Fisher Scientific). The sections were stored at −80°C.
Hybridization—The slides were postfixed in fresh 4% paraformaldehyde in Sorensen's 
phosphate buffer (0.03 M, pH 7.4) for 20 minutes, rinsed with Sorenson's phosphate buffer, 
and treated with proteinase K (1.0 μg/ml) for 4 minutes at room temperature. Sections were 
then treated with 0.1 M triethanolamine (3 minutes), followed by 0.25% acetic anhydride in 
0.1 M triethanolamine (10minutes) (Sigma- Aldrich, St Louis, MO). Sections were 
prehybridized for 1 hour at 58°C with hybridization buffer (50% formamide, 1x Denhardt's 
solution, 10% dextran sulfate, 100 μM dithiothreitol [DTT], 200 mM sodium chloride, 10 
mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0, 125 μg/ml tRNA; Sigma- Aldrich) and then 
quickly rinsed in 2xSSC buffer. The 35S-labeled antisense as well as sense riboprobes were 
heat-denatured, diluted with hybridization buffer, and used at a final concentration of 2×104 
cpm/μl. Subsequently, the sections were covered with glass coverslips, sealed, and 
hybridized in a moist chamber for at least 18 hours at 58°C. After hybridization, the slides 
were washed in 2x SSC buffer at 62°C four time with three changes, reacted with RNAse 
(20 μg/ml) for 30 minutes at 37°C, and washed in decreasing concentrations of SSC (2x, 1x, 
0.5x, 0.25x) at 58°C for 10 minutes each with three changes of each solution. Finally, the 
slides were washed in 0.1x SSC with 1mM DTT for 45 minutes at 58°C. The slides were 
dehydrated in 50%, 80% and 90% ethanol with 300mM Ammonium Acetate followed by 
100% ethanol for 2 minutes, placed side by side on a flat surface together with 
autoradiographic 14C microscales, and exposed to Hyperfilm-βmax (Amersham 
Biosciences, Piscataway, NJ) for 6 days at 4°C. The films were developed in D19 developer 
for 5 minutes, fixed in Kodak fixer for 5 minutes. The slides were then dipped in Kodak 
NTB-2 nuclear track emulsion and exposed for 21 days at 4°C. Thereafter, slides were 
developed in D19 developer for 2 minutes, fixed in Kodak fixer for 5 minutes, 
counterstained with hematoxylin, dehydrated, and coverslipped.
Film images were scanned (HP Scanjet 7400c) and digitized images processed in Adobe 
Photoshop (Mountain View, CA) and Macromedia FreeHand (San Francisco, CA). Contrast 
and brightness were adjusted in scanned images of films to compensate for uneven 
Jia et al. Page 7
Exp Neurol. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
illumination in brightfield images. Images of emulsion-coated slides were analyzed using a 
Nikon E800 microscope. Darkfield and brightfield images were captured using a Nikon DS-
L1 digital camera and illustrated in Adobe Photoshop and Macromedia FreeHand software 
programs. Contrast and brightness were adjusted in scanned images to match the original 
image seen in the microscope.
Statistical Analysis
Data were expressed as mean ± SEM. Infarct size, LDP bar graph and LC/MS/MS data were 
analyzed with one- or two- way analysis of variance (ANOVA), as appropriate, and post hoc 
Dunnett's multiple comparisons test using GraphPad Prism Software (version 3.1, SPSS Inc., 
La Jolla, CA, USA). Laser Doppler perfusion data were analyzed with two-way repeated 
measure ANOVA with Tukey's multiple comparisons test, while qPCR data were analyzed 
with two-way ANOVA with Tukey's multiple comparisons test. p < 0.05 was considered 
statistically significant.
Results
Expression and distribution of human CYP2J2 and CYP2C8 transgenes in mouse brain
In situ hybridization was used to determine endothelial expression of human CYP2J2 and 
CYP2C8 in brains of Tie2-CYP2J2 and Tie2-CYP2C8 female mice, respectively (Figure 1). 
[35S]-labeled antisense and sense cRNA probes prepared from the respective human 
sequences were used. Antisense probes produced hybridization signal in transgenic but not 
in WT littermate brain, and sense probes did not generate signal in transgenic brains (WT 
and sense hybridization not shown), indicating specificity of probe for the human 
transgenes. Localization of CYP2J2 and CYP2C8 transgenes broadly follow the vascular 
distribution in brain, as shown in representative sections from rostral to caudal forebrain in 
Figure 1A (a-c for CYP2J2, d-f for CYP2C8). It is of note that CYP2J2 mRNA is also 
expressed in ependymal cells lining the lateral or third ventricle in contrast to CYP2C8 
mRNA expression, which was limited to pial and parenchymal vessels. This can be clearly 
seen by comparing panels labeled c1 and c2 in Figure 1B and 1C. Higher magnification 
images are shown in 1B (CYP2J2) and 1C (CYP2C8), from top to bottom, of coronal 
sections through the rostrodorsal cortex (region labeled CTX in 1A), lateral ventricular area 
(LV) and olfactory cortex (CYP2J2)/ optic chiasm (CYP2C8), demonstrating vascular 
expression pattern for both transgenes. Another difference observed in expression between 
transgenes is the abundant expression of CYP2C8 in the choroid plexus, which is absent for 
CYP2J2 (not shown).
Transgenic expression of CYP2J2 and CYP2C8 in endothelium is protective against 
experimental stroke
To determine if endothelial expression of CYP2J2 or CYP2C8 epoxygenase alters outcome 
from experimental stroke, we compared cortical and striatal (caudate-putamen, CP) infarcts 
in Tie2-CYP2J2 and Tie2-CYP2C8 mice to those in WT, both in male and female mice. In 
males, both cortical and striatal infarcts were significantly smaller in transgenic mice 
compared to WT littermates (Figure 2A), with cortical infarct decreasing from 45.01 ± 3.1% 
of contralateral structure in WT to 25.75 ± 5.3% in Tie2-CYP2J2 and 22.10 ± 4.7% in Tie2-
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CYP2C8 mice. In females, striatal infarct was reduced from 70.36 ± 5.4% of contralateral 
structure in WT to 55.24 ± 5.2% in Tie2-CYP2J2 and 55.43 ± 7.1% in Tie2-CYP2C8 
(Figure 2B). However no reduction in infarct was observed in either the cortex or the 
hemisphere as a whole.
No differences were observed in body weight, anesthesia requirement or body temperature 
between WT and transgenic mice.
Transgenic expression of CYP2J2 in endothelium increases collateral blood flow in male 
mice
To determine if the decrease in infarct size in Tie2-CYP2J2 and Tie2-CYP2C8 transgenic 
mice was linked to increased CBF, we compared laser-Doppler cortical perfusion (LDP) 
during MCAO between WT and transgenic mice. Figure 3A shows that in males, LDP 
during MCAO was significantly higher in Tie2-CYP2J2 (19.76 ± 0.80% relative to 
baseline), but not in Tie2-CYP2C8 (15.29 ± 0.73%), compared to WT mice (12.09 
± 0.23%). In females, there were no differences in LDP during ischemia between WT (12.51 
± 0.35%) and either of the two transgenic mouse lines (Figure 3B). Following 5 minutes of 
reperfusion, LDP in males was significantly higher in Tie2-CYP2J2 (115.8 ± 6.8%) and 
Tie2-CYP2C8 (107.9 ± 5.7%) compared to WT (88.33 ± 6.1%). In females, LDP after 5 
minutes of reperfusion was also elevated in Tie2-CYP2C8 mice (120 ± 10.6) compared to 
both WT (98.17 ± 6.0) and Tie2-CYP2J2 mice (99.22 ± 5.9%).
We further carried out non-invasive optical microangiography (OMAG) in male WT and 
Tie2-CYP2J2 mice. We chose to evaluate microvascular perfusion in the CYP2J2 males as 
this was the only group to display increased LDP during the time of occlusion (Figure 3A). 
We found that despite filament withdrawal and reperfusion through proximal MCA branches 
(as indicated by the return in LDP to baseline in Fig 3A), distal microvascular perfusion was 
still impaired in the WT ischemic hemisphere (I) at 24 hours after MCAO (compared to 
contralateral hemisphere, Figure 3C). Importantly, male Tie2-CYP2J2 mice, as well as 
demonstrating higher LDP during time of occlusion, were also protected from delayed post-
ischemic microvascular hypoperfusion.
To determine whether the protection enjoyed by male mice with transgenic expression of 
CYP2J2 and CYP2C8 in endothelium was in fact due to increased CYP activity, rather than 
an off target effect of the transgene, infarct size and cortical perfusion after MCAO were 
measured in the presence of CYP inhibitor, MS-PPOH (Figure 4). Male mice were used 
since they displayed a more robust protection from MCAO than females (Figure 2). Mice 
were implanted with an osmotic pump containing 2.5 mg / ml MS-PPOH or vehicle 
(ethanol) prior to MCAO and kept for 24 hours after MCAO. Inhibition of CYP 
epoxygenase activity abolished the protective effect of the transgenes in male mice, as 
infarct size after MCAO was no longer different in Tie2-CYP2J2 or Tie2-CYP2C8 male 
mice compared to WT male mice (Figure 4A). Similarly, no differences were observed in 
LDP during MCAO between transgenic and WT mice (Figure 4B).
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Attenuation of post-ischemic inflammatory response in male mice with endothelial 
expression of CYP2J2 and CYP2C8
Because male Tie2-CYP2C8 mice were protected from ischemic injury compared to WT 
control mice, yet there were no differences in cortical perfusion during occlusion between 
the two groups, we investigated a possible anti-inflammatory mechanism of protection by 
CYP2C8. Using rt-qPCR, we measured pro-inflammatory cytokine expression in 
microvessels isolated from ischemic and contralateral hemispheres, as well as from naïve 
brains of male WT, Tie2-CYP2J2 and Tie2-CYP2C8 mice. We found that in WT mice, 
mRNA levels of both TNFα (Figure 5A) and IL1-β (Figure 5B) are significantly increased in 
microvessels from the ipsilateral hemisphere 24 hours following MCAO, compared to 
microvessels extracted from naïve brains. There was also a slight increase in contralateral 
hemisphere after MCAO (over levels in naive brain), but the increase was not statistically 
significant. Endothelial expression of CYP epoxygenase prevented pro-inflammatory 
cytokine expression after ischemia, as transgenic Tie2-CYP2J2 and Tie2-CYP2C8 mice did 
not show an increase in expression after MCAO.
Increase in fatty acid metabolites in Tie2-CYP2C8 male mice
Since CYP 450 epoxygenases metabolize AA to form EETs, we investigated the effect of 
endothelial expression of these two CYP isoforms on release of 11,12- and 14,15- EETs, 
also assessing their stable metabolites, 11-12- and 14,15- DHETs; these regioisomers were 
investigated since these are the primary metabolic products synthesized by CYP2J2 and 
CYP2C8 (Wu et al., 1996; Zeldin et al., 1995). Primary aortic endothelial cells from WT, 
Tie2-CYP2J2 and Tie2-CYP2C8 male mice were isolated and cultured and the release of 
EETs and DHETs into the culture medium by these cells was measured, both in the 
quiescent state and also following stimulation with 10 μM A23187 calcium ionophore for 10 
minutes which acts to liberate arachidonic acid from the plasma membrane. Our results 
show that, in the quiescent, unstimulated state, endothelial cells isolated from Tie2-CYP2J2 
mice release significantly higher concentrations of 11,12- EET and DHET into the medium 
compared to cells isolated from WT mice (14.05 ± 1.0 and 8.83 ± 0.8 pg/ million cells 
respectively for 11,12- EET and DHET combined). However, cells stimulated with A23187 
show a different response, in this paradigm cells isolated from Tie2-CYP2C8 mice release 
higher concentrations of 11,12-, and 14,15- EET and DHET combined compared to WT 
(27.14 ± 1.7 vs. 20.68 ± 2.0 and 65.76 ± 3.3 vs. 42.79 ± 5.4 pg/ million cells respectively), 
while cells isolated from both Tie2-CYP2J2 and Tie2-CYP2C8 transgenic lines release more 
14,15- EET than WT cells (18.44 ± 0.9 and 19.38 ± 0.6 compared to 12.96 ± 0.5 pg/million 
cells respectively). No difference was observed in levels of 11,12- EET itself following 
A23187 stimulation in endothelial cells derived from either transgenic line.
We also investigated the effect of endothelial expression of these two CYP isoforms on 
levels of fatty acid metabolites in cerebrospinal fluid (CSF) of male WT, Tie2-CYP2J2 and 
Tie2-CYP2J2 mice using liquid chromatography-tandem mass spectrometry (LC-MS/MS). 
We first measured levels of AA metabolites (Figure 7A). Although CSF levels of EETs were 
below detection, we were able to measure their stable metabolites, DHETs. Levels of both 
11,12- and 14,15-DHET were significantly increased in Tie2-CYP2C8 mice (0.21 ± 0.03 
and 0.33 ± 0.05 pg/ μl respectively) compared to WT (0.10 ± 0.02 and 0.18 ± 0.02 pg/ μl 
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respectively), while no increase was observed in mice expressing CYP2J2. CYP2C8-, but 
not CYP2J2-expressing mice also displayed increased levels of the LOX metabolite of AA, 
12-HETE, while levels of 5- and 15-HETE remained unchanged compared to WT. CSF 
levels of COX metabolites of AA, 6-keto-prostaglandin (6-keto-PGF1α), thromboxane B2 
(TXB2), prostaglandin F2α (PGF2α) and prostaglandin E2 (PGE2), were not different from 
WT in either of the transgenic strains. We also measured CYP products of linoleic acid and 
DHA metabolism (Figure 7B). Levels of the linoleic acid epoxides, 12,13- and 9,10- epoxy-
octadecamonoenoic acid (EpOME), were below the level of detection. We were able to 
quantify dihydroxy-octadecamonoenoic acid (12,13-DiHOME); however no difference 
among genotypes was observed. The epoxide product of docosahexaenoic acid (DHA) 
metabolism by CYP, 19,20-epoxydocosapentaenoic acid (19,20-EpDPE), showed no 
difference in CSF levels among genotypes; however, its metabolic product 19,20-
dihydroxydocosapentaenoic acid (19,20-DiHDPA) was increased in Tie2-CYP2C8 mice 
compared to WT control CSF (0.49 ± 0.06 to 1.33 ± 0.27 pg/ μl respectively).
Discussion
The main findings of our study are: 1) transgenic expression of CYP epoxygenase in 
vascular endothelium reduces infarct size after MCAO in male and female mice, decreasing 
infarct in the hemisphere as a whole in males but not females; 2) transgenic endothelial 
expression of CYP2J2, but not CYP2C8 enhances blood flow during MCAO in male, but not 
female mice, and improvement in microvascular perfusion is maintained during reperfusion; 
3) in males transgenic endothelial expression of either CYP2J2 or CYP2C8 attenuates post-
ischemic expression of pro-inflammatory cytokines in cerebral microvessels; 4) male Tie2-
CYP2J2 endothelial cells produce increased 11,12-EET in the quiescent state; 5) upon 
liberation of AA from the plasma membrane endothelial cells from both transgenic lines 
produce increased 14,15-EET, while Tie2-CYP2C8 also produce increased levels of 11,12 
EET and DHET, and 6) male Tie2-CYP2C8 mice have higher CSF levels of CYP 
metabolites of AA and DHA.
The biological activity of EETs is terminated through multiple pathways (Zeldin, 2001), 
including metabolism by soluble epoxide hydrolase (sEH) into less active vicinal diols 
referred to as dihydroxyeicosatrienoic acids (DHETs). We have previously demonstrated 
that mice with sEH gene deletion (sEH knockout, sEHKO) have higher circulating 14,15-
EET and enhanced collateral perfusion in response to focal vascular occlusion, resulting in 
reduced ischemic brain tissue damage (Zhang et al., 2008). These findings suggested that 
increasing EETs bioavailability by decreasing their metabolism may protect against stroke. 
Indeed, pharmacological inhibition of sEH was shown to reduce infarct size after MCAO in 
mice and to attenuate neuronal cell death in culture induced by oxygen-glucose deprivation 
(OGD) (Koerner et al., 2007, Zhang et al., 2007). Since sEHKO mice have global deletion of 
sEH, resulting in increased EETs in all cell types, we wondered about the specific 
contribution of endothelial EETs to protection from cerebral ischemia. In the current study 
we therefore examined the effect of transgenic overexpression of two cytochrome P450 
epoxygenase isoforms in vascular endothelium under control of the Tie2 promoter 
(Schlaeger et al., 1997) on blood flow and infarct size after MCAO in male and female mice. 
We examined males and females separately because of previous reports demonstrating sex 
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differences in P450 epoxygenase expression (Athirakul et al., 2008). We focused on 
CYP2C8 and CYP2J2 isoforms because these two human isoforms are highly expressed and 
major contributors to EETs biosynthesis in myocardial and vascular tissue (Enayetallah et 
al., 2004, Larsen et al., 2006). However, their contribution to the pathogenesis of 
cerebrovascular disease has not been well characterized to date.
Our data suggest that male mice are protected from ischemic injury by overexpression of 
CYP epoxygenase in vascular endothelium, regardless of whether the specific isoform is 
CYP2J2 or CYP2C8. The protection by CYP2J2, but not CYP2C8 overexpression was 
associated with increased blood flow during MCAO. Interestingly, Tie2-CYP2J2 mice also 
had improved microvascular perfusion at 24 hours after MCAO. Microvascular 
hypoperfusion at this point occurs as a result of multiple pathological mechanisms, including 
vasoconstriction, microthrombosis, inflammation, and endothelial injury and swelling. Our 
observation that CYP2J2 protects against this injury suggests that EETs either protect 
endothelial cells against the initial endothelial oxidative injury during ischemia-reperfusion 
or blocks downstream inflammatory and pro-thrombotic mechanisms.
Because infarct size was smaller in Tie2-CYP2C8, though unlike Tie2-CYP2J2, collateral 
blood flow was not increased, we searched for a non-vascular mechanism of protection by 
endothelial expression of CYP2C8. Since EETs possess anti-inflammatory properties in the 
vasculature (Node et al., 1999), and ischemia-induced expression of inflammatory cytokines 
in brain is attenuated in sEH knock-out mice (Koerner et al., 2008), we tested the hypothesis 
that transgenic endothelial expression CYP2C8 would attenuate MCAO-induced 
upregulation of cytokine mRNA expression in cerebral microvessels. We found that 
endothelial overexpression of either isoform prevented ischemia-induced cytokine 
expression that is observed in WT microvessels after MCAO. Our observation supports 
recent studies demonstrating anti-inflammatory roles for CYP2J2 both in cultured 
pulmonary endothelial cells and following ischemia/ reperfusion injury in the lung (Feng et 
al., 2013, Chen et al., 2015), and CYP2C8 in cultured human umbilical vein endothelial 
cells (Liu et al., 2014).
Following stimulation of aortic endothelial cells isolated from these mice with a calcium 
ionophore to induce AA release from the plasma membrane, a phenomenon which also 
occurs following ischemic insult, we see an increase in the production of EETs and their 
DHET metabolites by both CYP isoforms. It is interesting to note that despite Tie2-CYP2J2 
demonstrating both increased blood flow and decreased inflammatory cytokines, endothelial 
cells from these mice produce increased 14,15- EET following A23187 stimulation, but no 
increase in 11,12- EET. However the Tie2-CYP2C8 mice which were also protected from 
injury and had a reduction in inflammatory cytokines with no increase in blood flow during 
occlusion, showed increases in both 11,12- EET metabolites and 14,15- EET.
We also measured CSF levels of fatty acid metabolites in CSF collected from male mice. We 
found increased level of 11,12- and 14,15-DHET in Tie2-CYP2C8, likely reflecting 
increased synthesis of 11,12- and 14,15-EET, the two main metabolites produced by 
CYP2C8 (Daikh et al., 1994). Surprisingly we did not observe increased CSF DHETs in 
Tie2-CYP2J2, although we did observe increased EET/ DHET release by endothelial cells 
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from these mice. The lack of increased DHET in CSF may reflect limited substrate (AA) 
availability, especially since these were naïve mice and AA liberation from the plasma 
membrane occurs following injury or other stimulation. We also observed increased 19,20-
DiHDPA in CSF from Tie2-CYP2C8 mice, likely reflecting increased formation of 19,20-
EpDPE by CYP2C8 from DHA (Zhang et al., 2014), an essential fatty acid and the most 
abundant ω-3 fatty acid in neural tissues. A similar increase in plasma 19,20-EpDPE was 
also previously observed in Tie2-CYP2C8 (Shao et al., 2014). Finally, Tie2-CYP2C8 CSF 
also had increased levels of 12-HETE; although 12/15-HETEs are primarily produced via 
the lipoxygenase pathway, they have also been reported to be produced by members of the 
2C epoxygenase family, including CYP2C8 (Rifkind et al., 1995, Bylund et al., 1998).
In contrast to males, transgenic expression of CYP2J2 or CYP2C8 in endothelium did not 
alter CBF during MCAO in females and reduced infarct only in the striatum, though had no 
effect on the brain hemisphere as a whole. This observation suggests that the P450 
epoxygenase pathway plays a differential role in ischemic neuroprotection between males 
than females. Consistent with this concept, dilations to endothelium-derived hyperpolarizing 
factor (EDHF) in rat middle cerebral artery (MCA) are less pronounced in females 
compared to males (Golding et al., 2001). In coronary, cerebral, renal, and skeletal muscle 
circulations, EDHF has been suggested to be a cytochrome P450 epoxygenase metabolite 
(Alkayed et al., 1996, Fisslthaler et al., 1999, Fulton et al., 1992, Huang et al., 2000, Davis 
et al., 2011). The absence of protection in females by transgenic CYP expression in 
endothelium suggests that females use a different mechanism for blood flow regulation in 
the ischemic brain. One such mechanism could be endothelial nitric oxide (eNOS), which is 
enhanced by chronic estrogen treatment (Athirakul et al., 2008, Goetz et al., 1994). For 
example, substance P- and shear stress-induced dilation of skeletal muscle arterioles was 
greater in female than male rats, linked to greater release of NO in females (Huang and 
Kaley, 2004, Huang et al., 1998, Huang et al., 1997). However, when eNOS is absent, as in 
the case of eNOS knockout mice, females use the P450 epoxygenase pathway to mediate 
flow-induced dilation in skeletal muscle arterioles (Huang et al., 2000).
Alternatively, it is perhaps not surprising that transgenic expression of the CYP isoforms did 
not protect female mice from ischemic damage. Female WT mice sustain smaller infarcts 
than males following MCAO while also maintaining higher CBF during occlusion. They 
also have lower sEH levels in the brain and higher circulating EETs than males. We have 
previously demonstrated that the sex difference in infarct size is abolished in global sEH 
knock-out mice, where male infarct size is reduced to that observed in females (Zhang et al., 
2014). Overexpression of CYP enzymes in one cell type in the brain may therefore not 
afford additional benefit to females who already benefit from higher levels of EETs. 
Whereas males, who have lower EETs, would benefit from increased generation of EETs by 
the endothelium. Although we did not carry out a side-by-side comparison of expression 
levels of the transgenes between males and females, we do demonstrate robust expression of 
both transgenes in the female brain by in situ hybridization. Therefore the lack of protection 
from ischemic insult in female WT vs. Tie2 mice does not appear to be due to a lack of 
expression of the Tie2- driven CYP enzymes.
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In summary, the current study examined the effects of transgenic expression of cytochrome 
P450 epoxygenase in vascular endothelium on focal cerebral ischemic injury in mice. We 
demonstrate that endothelial overexpression of two distinct human CYP isoforms is 
protective in male mice. The mechanism of protection is dependent on which CYP isoform 
is expressed, which is likely mediated by suppression of ischemia-induced inflammation in 
Tie2-CYP2C8 mice, and a combination of anti-inflammatory mechanism with enhanced 
blood flow in Tie2-CYP2J2 mice. In contrast, transgenic expression of CYP epoxygenase in 
females did not alter blood flow or hemispheric infarct size after MCAO. These findings 
suggest that the efficacy and mechanism of protection of any therapeutic strategies targeting 
the cytochrome P450 epoxygenase pathway may be influenced by sex and the specific CYP 
isoform involved.
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Highlights
• Transgenic endothelial CYP2J2/ CYP2C8 expression reduces MCAO infarct in 
male mice, and to a lesser extent in female mice.
• Endothelial CYP2J2, but not CYP2C8, increases collateral blood flow in male 
mice.
• Endothelial CYP2J2/ CYP2C8 reduces post-ischemic inflammatory response in 
male mice.
• Endothelial CYP epoxygenase is a potential therapeutic target in male stroke 
patients.
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Figure 1. 
Expression and distribution of human CYP2J2 and CYP2C8 mRNA in the brain of 
transgenic female mice by in situ hybridization (ISH). A. Bright-field film images 
illustrating the distribution of CYP2J2 (top) and CYP2C8 (bottom) mRNA (dark stain) from 
rostral to caudal in mouse forebrain transfected the respective human transcripts (a-c; d-f). B 
& C. Emulsion autoradiograms of human CYP2J2 (B) and CYP2C8 (C) mRNA in Tie2-
CYP2J2 and Tie2-CYP2C8 mouse forebrain respectively. Photomicrographs of dark-field 
(a1-d1) and bright-field (a2-d2) at low and high power views, illustrating respective mRNA 
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signal (white grains in a1-d1, dark grains in a2-d2) within coronal sections through the 
rostrodorsal cortex (CTX; a, b), lateral ventricular area (LV; c) and olfactory cortex in Tie2-
CYP2J2 or supraoptic nucleus area in Tie2-CYP2C8 brains (OC; d). Boxed areas from a1-
d1 are shown as high-power bright-field images in a2-d2, illustrating autoradiographic 
grains (mRNA) over blood vessels (a,b), ependymal lining of the lateral ventricle (c) and 
along the ventral surface of the brain (d). Scale bar = 200 μm (a1-d1) and 50 μm (a2-d2). CP, 
caudate putamen; CTX, cortex; LV, lateral ventricle; OC, optic chiasm; 3V, third ventricle.
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Figure 2. 
Transgenic expression of CYP2J2 and CYP2C8 epoxygenase in endothelium is protective 
against ischemic brain injury in male (A) and female (B) mice. Infarction was assessed 24 
hours after MCAO by TTC in cortex (CTX) and caudate-putamen (CP). Total hemispheric 
infarct is also presented as a direct measure (HMSPH) and after correcting for edema 
(Corrected). * p<0.05 versus WT (n=10 per group).
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Figure 3. 
Laser-Doppler cerebrocortical perfusion (LDP) during MCAO in WT, Tie2-CYP2J2 and 
Tie2-CYP2C8 male and female mice. A. Tie2-CYP2J2, but not Tie-2-CYP2C8 males, 
displayed significantly higher perfusion of the MCA territory during occlusion compared to 
corresponding WT males. Both Tie2-CYP2J2 and Tie2-CYP2C8 displayed higher LDP 
compared to WT following 5 minutes of reperfusion. B. No differences were observed in 
perfusion between female transgenic and WT mice during occlusion (n=10 per group). After 
5 minutes of reperfusion Tie2CYP2C8 mice displayed higher LDP compared to both WT 
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and Tie2-CYP2J2 mice. Line graph displays perfusion at 15 minute intervals during 
occlusion and immediately following reperfusion (RP) relative to baseline (BL). Bar graph 
displays average perfusion throughout the occlusion period. * and # denote p<0.05 CYP2J2 
and CYP2C8, respectively, versus WT; $ denotes p<0.05 Tie2-CYP2J2 versus Tie2-
CYP2C8 (n=10 per group). C. Optical microangiography (OMAG) images illustrating 
increased microvascular cortical perfusion of ipsilateral ischemic (I) hemisphere in male 
Tie2-CYP2J2 brain 24 hours after MCAO compared to WT.
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Figure 4. 
Cytochrome P450 epoxygenase (CYP) inhibition abolishes protection in Tie2-CYP2J2 and 
Tie2-CYP2C8 male mice. A. Infarct size at 24 hours after MCAO was no different in 
transgenic compared to WT male mice in cortex (CTX), caudate- putamen (CP) or total 
hemisphere with (Corrected) or without correction for edema (HMSPH). B. Laser Doppler 
perfusion, at 15 minute intervals during and immediately after occlusion (left), or averaged 
over the occlusion period (right), was not different in male transgenic compared to WT male 
mice in the presence of CYP inhibitor MS-PPOH. p>0.05 (n = 5 per group).
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Figure 5. 
Transgenic endothelial expression of CYP2J2 and CYP2C8 epoxygenase prevents ischemia-
induced cytokine expression after MCAO in male mice. Levels of TNFα (A) and IL1-β (B) 
transcripts were assessed by qPCR in microvessels isolated from WT, Tie2-CYP2J2 and 
Tie2-CYP2C8 brains, at 24 hours after MCAO (both ipsilateral and contralateral 
hemispheres) or from naïve mice (whole brain). In WT mice, a significant increase in both 
TNFα and IL1-β mRNA was observed in microvessels from the ipsilateral hemisphere 
compared to naïve mice. No such increase was observed in microvessels from either Tie2-
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CYP2J2 or Tie2-CYP2C8 transgenic mice. * p<0.05 versus naive (6-9 animals per group; 
vessels from 3 animals were combined in one pooled sample, and 2-3 independent pooled 
samples were analyzed in each group).
Jia et al. Page 26
Exp Neurol. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. 
Increased release of EETs and DHETs by endothelial cells from male Tie2-CYP2J2 and 
Tie2-CYP2C8 mice. A. Levels of 11,12-EET, 11,12-DHET and 11,12-EET + DHET are 
increased in medium conditioned by aortic endothelial cells isolated from Tie2-CYP2J2 
compared to WT mice. No increase is observed in the 14,15- regioisomers or in medium 
collected from cells conditioned by Tie2-CYP2C8 cells. B. Upon stimulation of endothelial 
cells with A23187 calcium ionophore, cells isolated from both Tie2-CYP2J2 and Tie2-
CYP2C8 mice release increased levels of 14,15-EET compared to WT cells. CYP2C8 
endothelial cells also display increased DHET and EET + DHET levels of both 11,12- and 
14,15- regioisomers in cell- conditioned medium, compared to WT cells.
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Figure 7. 
Fatty acid metabolites in CSF from male WT, Tie2-CYP2J2 and Tie2-CYP2C8 mice. A. 
Metabolites of arachidonic acid (AA) by CYP and LOX, but not COX enzymes were 
increased in Tie2-CYP2C8, but not Tie2-CYP2J2 mice, compared to WT. B. 12,13-
DiHOME, a product of linoleic acid metabolism by CYP and sEH, was not different among 
groups. The CYP product of DHA metabolism, 19,20-EpDPE, was unaltered in CSF; 
however, its sEH metabolite 19,20-DiHDPA was increased in CSF from Tie2-CYP2C8 
compared to WT mice. * p<0.05 versus WT (n=16 WT, 15 Tie2-CYP2J2, 11 Tie2-
CYP2C8).
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